CA3055308A1 - Methods of treating cancer - Google Patents

Methods of treating cancer Download PDF

Info

Publication number
CA3055308A1
CA3055308A1 CA3055308A CA3055308A CA3055308A1 CA 3055308 A1 CA3055308 A1 CA 3055308A1 CA 3055308 A CA3055308 A CA 3055308A CA 3055308 A CA3055308 A CA 3055308A CA 3055308 A1 CA3055308 A1 CA 3055308A1
Authority
CA
Canada
Prior art keywords
compound
cancer
hepatocellular carcinoma
fxr
fxr agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3055308A
Other languages
English (en)
French (fr)
Inventor
Antonio MOSCHETTA
Jesus Maria Banales Asurmedi
Luis Bujanda Fernandez De Pierola
Maria Jesus Perugorria Montiel
Oihane Erice AZPARREN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CA3055308A1 publication Critical patent/CA3055308A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3055308A 2017-03-07 2017-09-21 Methods of treating cancer Abandoned CA3055308A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468259P 2017-03-07 2017-03-07
US62/468,259 2017-03-07
PCT/US2017/052663 WO2018164715A1 (en) 2017-03-07 2017-09-21 Methods of treating cancer

Publications (1)

Publication Number Publication Date
CA3055308A1 true CA3055308A1 (en) 2018-09-13

Family

ID=63447943

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3055308A Abandoned CA3055308A1 (en) 2017-03-07 2017-09-21 Methods of treating cancer

Country Status (9)

Country Link
EP (1) EP3592357A4 (https=)
JP (1) JP7042836B2 (https=)
KR (1) KR20190122251A (https=)
CN (1) CN110430882A (https=)
AU (1) AU2017402623A1 (https=)
CA (1) CA3055308A1 (https=)
IL (1) IL269123A (https=)
TW (1) TW201832768A (https=)
WO (1) WO2018164715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022011037A2 (en) * 2020-07-07 2022-01-13 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
WO2023043375A2 (en) * 2021-09-16 2023-03-23 Agency For Science, Technology And Research Modulation of tjp1 expression to treat liver diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107475A1 (en) * 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
AU2013352288B2 (en) * 2012-11-28 2017-11-23 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US11578097B2 (en) * 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
WO2018164715A1 (en) 2018-09-13
KR20190122251A (ko) 2019-10-29
TW201832768A (zh) 2018-09-16
EP3592357A1 (en) 2020-01-15
CN110430882A (zh) 2019-11-08
JP2020510009A (ja) 2020-04-02
JP7042836B2 (ja) 2022-03-28
AU2017402623A1 (en) 2019-09-26
EP3592357A4 (en) 2021-01-13
IL269123A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US10369160B2 (en) Methods of treating cancer
WO2021263180A1 (en) Use of oxygenated cholesterol sulfates for cancers and non-cancerous transformations related to epstein-barr virus
EP3411058B1 (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
US20230048576A1 (en) Compounds for the treatment of neuropathic pain
CA3055308A1 (en) Methods of treating cancer
US20180256600A1 (en) Methods of treating cancer
US20220184099A1 (en) Methods of using obeticholic acid
US20260102466A1 (en) ß-DEFENSIN-2 PEPTIDE FOR INHIBITING CELL GROWTH OF COLON CANCER
US20240050515A1 (en) Methods and compositions for treating cd44+ cancers
US20230272103A1 (en) Cd44-modulating compositions for methods for treating cancers and ascites
HK40010220A (en) Methods of treating cancer
WO2021022213A1 (en) Intravenous vitamin c therapy protocol for the treatment of cancer
CA2925305A1 (en) Combination therapy with a6 and chemotherapeutic agents for the treatment of cancer
HK40001457B (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
HK40001457A (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
HK1260434A1 (en) Methods of treating cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240103